Breaking Finance News

Zacks Investment Research recorded C R Bard Inc (NYSE:BCR), raising its target price to $353.00 today

C R Bard Inc (NYSE:BCR) had its stock price target increased to $353.00 by Zacks Investment Research in an issued report announced 6/21/2017. The upped price target suggests a potential upside of 0.12% from the company's previous stock price close.

Boasting a price of $315.73, C R Bard Inc (NYSE:BCR) traded -0.29% lower on the day. With the last stock price close up 7.45% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. C R Bard Inc has recorded a 50-day average of $320.16 and a two hundred day average of $297.42. Volume of trade was down over the average, with 393,428 shares of BCR changing hands under the typical 468,467

Performance Chart

C R Bard Inc (NYSE:BCR)

With a total market value of $0, C R Bard Inc has price-earnings ratio of 41.95 with a one year low of $203.63 and a one year high of $324.58 .

A total of 14 equity analysts have released a ratings update on BCR. Two equity analysts rating the company a strong buy, four equity analysts rating the company a buy, fourteen equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $226.21.

Brief Synopsis About C R Bard Inc (NYSE:BCR)

C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.